RSS

erenumab

The European Commission (EC) has approved Novartis’ Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraines per month. more

News

Two recently published clinical studies have demonstrated a new approach using antibodies to target specific chemicals in the brain may help significantly reduce the incidence and severity of migraines. more

News